FDMT•benzinga•
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $39
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 14, 2024 by benzinga